Physician profile
Gary Bregman
NPI 1407972649
$1,375.18
in general payments reported to CMS, 2019-2025
14 companies · $47.16 in 2025
The $47.16 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2023: $673 · 2024: $293 · 2025: $47.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $331.84 | 2023-2025 | Euflexxa |
| Zimmer Biomet Holdings, INC. | $244.53 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $237.79 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $181.69 | 2023-2024 | Iovera, Zilretta |
| Grifols USA, LLC | $124.99 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $59.00 | 2024 | |
| Globus Medical, INC. | $42.82 | 2023 | Distal Femur Plate System |
| Molnlycke Health Care US, LLC | $30.29 | 2023 | Mepilex Border Post-Op Ag, Avance |
| Polynovo North America LLC | $25.98 | 2025 | Novosorb Btm |
| Depuy Synthes Sales INC. | $21.47 | 2024 | Monovisc |
| Kci USA, INC. | $21.06 | 2023 | Prevena |
| Kerecis Limited | $19.20 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Ethicon US, LLC | $18.34 | 2023 | Dermabond Prineo |
| Avanos Medical | $16.18 | 2023 | Coolief* Cooled Radiofrequency |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bregman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.